drug
DA-1726
Phase 1updated 6mo agoby $MTVA MetaVia Inc.
Phase 1community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying DA-1726
News(1)
- MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver diseaseMetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial. Encouraged by the data, MetaVia plans to start a phase 2 trial in alcohol-assoc…fiercebiotech · 9d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that